These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32820678)

  • 1. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of
    Harada T; Kato R; Sueda Y; Funaki Y; Takata M; Okazaki R; Hasegawa Y; Yamasaki A
    Mod Rheumatol; 2021 May; 31(3):629-635. PubMed ID: 32820678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
    Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
    J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.
    Utsunomiya M; Dobashi H; Odani T; Saito K; Yokogawa N; Nagasaka K; Takenaka K; Soejima M; Sugihara T; Hagiyama H; Hirata S; Matsui K; Nonomura Y; Kondo M; Suzuki F; Tomita M; Kihara M; Yokoyama W; Hirano F; Yamazaki H; Sakai R; Nanki T; Koike R; Kohsaka H; Miyasaka N; Harigai M
    Arthritis Res Ther; 2017 Jan; 19(1):7. PubMed ID: 28100282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
    Park JW; Curtis JR; Kim MJ; Lee H; Song YW; Lee EB
    Arthritis Res Ther; 2019 Sep; 21(1):207. PubMed ID: 31521185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.
    Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K
    Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study.
    Yamashita K; Shimomura Y; Ikesue H; Muroi N; Yoshimoto A; Hashida T
    BMC Infect Dis; 2021 Jul; 21(1):664. PubMed ID: 34238239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
    Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
    Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
    Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
    BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
    Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
    J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional-dose Versus Half-dose Sulfamethoxazole-trimethoprim for the Prophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Disease: A Non-blind, Randomized Controlled Trial.
    Abe Y; Fujibayashi K; Nishizaki Y; Yanagisawa N; Nojiri S; Nakano S; Tada K; Yamaji K; Tamura N
    Acta Med Okayama; 2019 Feb; 73(1):85-89. PubMed ID: 30820060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV: A Multicenter, Retrospective Observational Cohort Study.
    Nagai T; Matsui H; Fujioka H; Homma Y; Otsuki A; Ito H; Ohmura S; Miyamoto T; Shichi D; Tomohisa W; Otsuka Y; Nakashima K
    Chest; 2024 Jan; 165(1):58-67. PubMed ID: 37574166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.
    Carr A; Tindall B; Penny R; Cooper DA
    AIDS; 1992 Feb; 6(2):165-71. PubMed ID: 1558714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study.
    Otani T; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Hirata S; Fujitaka K; Hamada H; Sugiyama E; Hattori N
    Pulm Pharmacol Ther; 2021 Apr; 67():101999. PubMed ID: 33571651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.
    Park JW; Curtis JR; Moon J; Song YW; Kim S; Lee EB
    Ann Rheum Dis; 2018 May; 77(5):644-649. PubMed ID: 29092853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids.
    Jinno S; Akashi K; Onishi A; Nose Y; Yamashita M; Saegusa J
    Rheumatol Int; 2022 Aug; 42(8):1403-1409. PubMed ID: 34263352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant.
    Chapman FA; Dickerson JE; Daly C; Clancy M; Geddes C
    Ann Transplant; 2019 Dec; 24():625-630. PubMed ID: 31806862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection.
    Kosaka M; Ushiki A; Ikuyama Y; Hirai K; Matsuo A; Hachiya T; Hanaoka M
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: A single-center retrospective observational cohort study.
    Nakashima K; Aoshima M; Nakashita T; Hara M; Otsuki A; Noma S; Misawa M; Otsuka Y; Motojima S
    J Microbiol Immunol Infect; 2018 Dec; 51(6):810-820. PubMed ID: 28779879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
    Park SY; Jung JH; Kwon H; Shin S; Kim YH; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
    Transpl Infect Dis; 2020 Apr; 22(2):e13245. PubMed ID: 31943590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.